GlassScriptPhysician profile
Ronald S Weiss
NPI 1912910019
$4,610.69
in general payments reported to CMS, 2019-2025
26 companies · $778 in 2025
The $778 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $298 · 2021: $471 · 2022: $663 · 2023: $339 · 2024: $1,509 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085 · Travel and Lodging: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.25 |
| Travel and Lodging | $540.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,681.09 | 2019-2025 | Clareon, Centurion, Rocklatan |
| Allergan, INC. | $513.65 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $409.99 | 2019-2023 | |
| Abbvie INC. | $402.85 | 2022-2025 | Durysta |
| Bausch & Lomb Americas INC. | $202.82 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $178.39 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $154.76 | 2019-2021 | |
| New World Medical,INC. | $136.41 | 2022 | |
| Apellis Pharmaceuticals, INC. | $130.79 | 2022-2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $114.42 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $107.10 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $100.28 | 2022-2024 | Iyuzeh |
| Merz Pharmaceuticals, LLC | $82.56 | 2022-2023 | Xeomin |
| Regeneron Healthcare Solutions, INC. | $60.60 | 2023-2024 | Eylea, Eylea Hd |
| Biotissue Holdings INC. | $42.96 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $38.73 | 2019-2022 | |
| Ivantis, INC | $37.99 | 2021 | |
| Alimera Sciences, INC. | $33.47 | 2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $25.79 | 2024 | Vabysmo |
| Shire North American Group INC | $25.52 | 2019 | |
| Oyster Point Pharma, INC. | $25.36 | 2023 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $23.75 | 2025 | |
| Abiomed | $22.07 | 2024 | Impella |
| Astellas Pharma US INC | $20.53 | 2025 | Izervay |
| Glaukos Corporation | $20.48 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Mallinckrodt Enterprises LLC | $18.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.